In a brief 30-minute reaction, the top performing enzyme achieved a 63% conversion to the desired chiral alcohol and delivered perfect stereoselectivity, meeting the stringent purity requirements for pharmaceutical ingredients.
Our client, a leader in biotechnology, had amassed a proprietary metagenomics database of 1.5 billion protein sequences. This vast resource held immense potential for identifying novel sequences with industrial value, but its sheer scale posed a critical challenge: traditional methods for enzyme discovery were too inefficient to be viable.
With sequence identities as low as 20-30% to known homologs, standard homology-based screening was impractical. The client was unable to effectively identify novel enzymes and unlock the value hidden within their data asset.
Zymvol implemented a targeted, multi-stage computational approach focused on laccases. Laccases were selected as the initial target due to their significant industrial value as powerful oxidases that use molecular oxygen and release only water, as well as our team’s deep expertise in their engineering and application.
Our methodology transformed the discovery process from a numbers game into a precision-driven search: